STOCK TITAN

[Form 4] NovoCure Limited Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

John Wiley & Sons, Inc. (WLYB) has filed a Form 144 indicating an intended sale of 5,665 shares of its common stock through UBS Financial Services on the NYSE, with an aggregate market value of $250,053. Based on the figures supplied, the reference price is roughly $44 per share. The shares to be sold represent approximately 0.013 % of the company’s 44.62 million shares outstanding, making the planned disposition immaterial in percentage terms.

The stock was acquired via the vesting of multiple tranches of restricted stock units (RSUs) and performance share units (RPSUs) granted between April 2021 and April 2023. Tranche sizes range from 191 to 1,565 shares, reflecting normal equity-compensation practices. The filer reported no sales during the prior three-month period and certified the absence of undisclosed material adverse information.

Form 144 is a notice of proposed, not completed, sales. The filing does not disclose the seller’s identity, whether a Rule 10b5-1 trading plan exists, or final execution prices. Given the modest size of the transaction and its origin from routine incentive-compensation vesting, the event is unlikely to influence WLYB’s share price materially, but it remains a data point for investors monitoring insider-selling patterns.

John Wiley & Sons, Inc. (WLYB) ha presentato un modulo Form 144 che indica l'intenzione di vendere 5.665 azioni ordinarie tramite UBS Financial Services sulla NYSE, per un valore di mercato complessivo di 250.053 $. In base ai dati forniti, il prezzo di riferimento è di circa 44 $ per azione. Le azioni da vendere rappresentano circa lo 0,013% delle 44,62 milioni di azioni in circolazione, rendendo la disposizione pianificata irrilevante in termini percentuali.

Le azioni sono state acquisite tramite il consolidamento di più tranche di unità azionarie vincolate (RSU) e unità azionarie legate alle performance (RPSU) assegnate tra aprile 2021 e aprile 2023. Le dimensioni delle tranche variano da 191 a 1.565 azioni, in linea con le normali pratiche di compensazione azionaria. Il soggetto che ha effettuato la segnalazione ha dichiarato nessuna vendita nel trimestre precedente e ha certificato l'assenza di informazioni rilevanti non divulgate.

Il modulo Form 144 è una notifica di vendita proposta, non ancora completata. La comunicazione non rivela l'identità del venditore, l'esistenza di un piano di trading secondo la regola 10b5-1, né i prezzi finali di esecuzione. Considerando la dimensione modesta della transazione e la sua origine da un normale consolidamento di incentivi, l'evento è poco probabile che influenzi materialmente il prezzo delle azioni WLYB, ma resta un dato utile per gli investitori che monitorano i modelli di vendita interna.

John Wiley & Sons, Inc. (WLYB) ha presentado un Formulario 144 que indica la intención de vender 5.665 acciones ordinarias a través de UBS Financial Services en la NYSE, con un valor de mercado total de 250.053 $. Según las cifras proporcionadas, el precio de referencia es aproximadamente 44 $ por acción. Las acciones a vender representan aproximadamente el 0,013 % de las 44,62 millones de acciones en circulación de la compañía, haciendo que la disposición planeada sea insignificante en términos porcentuales.

Las acciones fueron adquiridas mediante la consolidación de múltiples tramos de unidades restringidas de acciones (RSU) y unidades de acciones por desempeño (RPSU) otorgadas entre abril de 2021 y abril de 2023. El tamaño de los tramos varía de 191 a 1.565 acciones, reflejando prácticas normales de compensación en acciones. El declarante informó no haber realizado ventas en el período previo de tres meses y certificó la ausencia de información adversa material no divulgada.

El Formulario 144 es un aviso de ventas propuestas, no completadas. La presentación no revela la identidad del vendedor, si existe un plan de negociación según la Regla 10b5-1, ni los precios finales de ejecución. Dado el tamaño modesto de la transacción y su origen en la consolidación rutinaria de incentivos, el evento es poco probable que influya materialmente en el precio de las acciones de WLYB, pero sigue siendo un dato para los inversores que monitorean patrones de ventas internas.

John Wiley & Sons, Inc. (WLYB)는 NYSE에서 UBS Financial Services를 통해 보통주 5,665주를 매도할 예정임을 알리는 Form 144를 제출했으며, 총 시장 가치는 250,053달러에 달합니다. 제공된 수치에 따르면 기준 가격은 주당 약 44달러입니다. 매도 예정인 주식은 회사의 총 발행 주식 4,462만 주 중 약 0.013%에 해당해, 비율상으로는 미미한 규모입니다.

해당 주식은 2021년 4월부터 2023년 4월 사이에 부여된 제한 주식 단위(RSU)와 성과 주식 단위(RPSU)의 여러 트랜치가 만기되면서 취득한 것입니다. 트랜치 크기는 191주에서 1,565주 사이로, 일반적인 주식 보상 관행을 반영합니다. 신고자는 지난 3개월 동안 판매가 없었다고 보고했으며, 공개되지 않은 중대한 부정적 정보가 없음을 인증했습니다.

Form 144는 제안된 판매에 대한 통지이며, 아직 완료된 것은 아닙니다. 제출서에는 판매자의 신원, Rule 10b5-1 거래 계획 존재 여부, 최종 실행 가격이 공개되어 있지 않습니다. 거래 규모가 작고 일상적인 인센티브 보상 만기에서 비롯된 점을 고려할 때, 이번 사건이 WLYB 주가에 중대한 영향을 미칠 가능성은 낮지만, 내부자 매도 패턴을 모니터링하는 투자자들에게는 참고 자료가 됩니다.

John Wiley & Sons, Inc. (WLYB) a déposé un formulaire 144 indiquant une intention de vente de 5 665 actions ordinaires via UBS Financial Services sur le NYSE, pour une valeur marchande totale de 250 053 $. Selon les chiffres fournis, le prix de référence est d'environ 44 $ par action. Les actions à vendre représentent environ 0,013 % des 44,62 millions d'actions en circulation, ce qui rend cette opération insignifiante en termes de pourcentage.

Les actions ont été acquises via la levée de plusieurs tranches d'unités d'actions restreintes (RSU) et d'unités d'actions de performance (RPSU) attribuées entre avril 2021 et avril 2023. La taille des tranches varie de 191 à 1 565 actions, reflétant les pratiques habituelles de rémunération en actions. Le déclarant a signalé aucune vente au cours des trois derniers mois et a certifié l'absence d'informations défavorables non divulguées.

Le formulaire 144 est un avis de ventes proposées, non encore réalisées. Le dépôt ne révèle pas l'identité du vendeur, l'existence éventuelle d'un plan de trading selon la règle 10b5-1, ni les prix finaux d'exécution. Étant donné la taille modeste de la transaction et son origine dans la levée habituelle de rémunérations incitatives, cet événement est peu susceptible d'influencer significativement le cours de l'action WLYB, mais reste une donnée à considérer pour les investisseurs surveillant les tendances de ventes internes.

John Wiley & Sons, Inc. (WLYB) hat ein Formular 144 eingereicht, das den beabsichtigten Verkauf von 5.665 Stammaktien über UBS Financial Services an der NYSE mit einem Gesamtmarktwert von 250.053 $ anzeigt. Basierend auf den angegebenen Zahlen liegt der Referenzpreis bei etwa 44 $ pro Aktie. Die zum Verkauf stehenden Aktien entsprechen ungefähr 0,013 % der 44,62 Millionen ausstehenden Aktien des Unternehmens, was die geplante Veräußerung in prozentualer Hinsicht unbedeutend macht.

Die Aktien wurden durch das Vesting mehrerer Tranchen von Restricted Stock Units (RSUs) und Performance Share Units (RPSUs) erworben, die zwischen April 2021 und April 2023 gewährt wurden. Die Tranchengrößen reichen von 191 bis 1.565 Aktien und spiegeln übliche Praktiken der Aktienvergütung wider. Der Meldende gab an, im vorangegangenen Dreimonatszeitraum keine Verkäufe getätigt zu haben, und bestätigte das Fehlen nicht offengelegter wesentlicher negativer Informationen.

Formular 144 ist eine Mitteilung über geplante, noch nicht abgeschlossene Verkäufe. Die Einreichung offenbart nicht die Identität des Verkäufers, ob ein Rule 10b5-1 Handelsplan besteht, oder die endgültigen Ausführungspreise. Angesichts der moderaten Größe der Transaktion und ihres Ursprungs aus routinemäßigem Anreiz-Vesting ist es unwahrscheinlich, dass das Ereignis den Aktienkurs von WLYB wesentlich beeinflusst, bleibt jedoch ein Datenpunkt für Investoren, die Insider-Verkaufsmuster beobachten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small insider Form 144 (5,665 shares) from RSU/RPSU vesting; negligible at 0.013 % float—market impact expected to be minimal.

The filing signals intent rather than execution, so liquidity effects may never materialize. Even if fully executed, $250k in value is minor versus Wiley’s daily trading volume and market cap. The sales stem from normal equity-compensation vesting cycles and are spread across grants from 2021-2023, suggesting no abrupt change in insider sentiment. I view the disclosure as informational only and rate the impact neutral.

TL;DR: Routine equity-compensation liquidation; no red flags on governance or undisclosed information, hence neutral for investors.

Form 144 requires certification that the seller is unaware of non-public adverse information—this strengthens governance transparency. Absence of clustered insider selling or large percentage ownership changes indicates standard personal liquidity management. Because details on any Rule 10b5-1 plan are absent, investors may wish to verify future Form 4 filings for actual transactions, but nothing in this notice suggests heightened governance risk.

John Wiley & Sons, Inc. (WLYB) ha presentato un modulo Form 144 che indica l'intenzione di vendere 5.665 azioni ordinarie tramite UBS Financial Services sulla NYSE, per un valore di mercato complessivo di 250.053 $. In base ai dati forniti, il prezzo di riferimento è di circa 44 $ per azione. Le azioni da vendere rappresentano circa lo 0,013% delle 44,62 milioni di azioni in circolazione, rendendo la disposizione pianificata irrilevante in termini percentuali.

Le azioni sono state acquisite tramite il consolidamento di più tranche di unità azionarie vincolate (RSU) e unità azionarie legate alle performance (RPSU) assegnate tra aprile 2021 e aprile 2023. Le dimensioni delle tranche variano da 191 a 1.565 azioni, in linea con le normali pratiche di compensazione azionaria. Il soggetto che ha effettuato la segnalazione ha dichiarato nessuna vendita nel trimestre precedente e ha certificato l'assenza di informazioni rilevanti non divulgate.

Il modulo Form 144 è una notifica di vendita proposta, non ancora completata. La comunicazione non rivela l'identità del venditore, l'esistenza di un piano di trading secondo la regola 10b5-1, né i prezzi finali di esecuzione. Considerando la dimensione modesta della transazione e la sua origine da un normale consolidamento di incentivi, l'evento è poco probabile che influenzi materialmente il prezzo delle azioni WLYB, ma resta un dato utile per gli investitori che monitorano i modelli di vendita interna.

John Wiley & Sons, Inc. (WLYB) ha presentado un Formulario 144 que indica la intención de vender 5.665 acciones ordinarias a través de UBS Financial Services en la NYSE, con un valor de mercado total de 250.053 $. Según las cifras proporcionadas, el precio de referencia es aproximadamente 44 $ por acción. Las acciones a vender representan aproximadamente el 0,013 % de las 44,62 millones de acciones en circulación de la compañía, haciendo que la disposición planeada sea insignificante en términos porcentuales.

Las acciones fueron adquiridas mediante la consolidación de múltiples tramos de unidades restringidas de acciones (RSU) y unidades de acciones por desempeño (RPSU) otorgadas entre abril de 2021 y abril de 2023. El tamaño de los tramos varía de 191 a 1.565 acciones, reflejando prácticas normales de compensación en acciones. El declarante informó no haber realizado ventas en el período previo de tres meses y certificó la ausencia de información adversa material no divulgada.

El Formulario 144 es un aviso de ventas propuestas, no completadas. La presentación no revela la identidad del vendedor, si existe un plan de negociación según la Regla 10b5-1, ni los precios finales de ejecución. Dado el tamaño modesto de la transacción y su origen en la consolidación rutinaria de incentivos, el evento es poco probable que influya materialmente en el precio de las acciones de WLYB, pero sigue siendo un dato para los inversores que monitorean patrones de ventas internas.

John Wiley & Sons, Inc. (WLYB)는 NYSE에서 UBS Financial Services를 통해 보통주 5,665주를 매도할 예정임을 알리는 Form 144를 제출했으며, 총 시장 가치는 250,053달러에 달합니다. 제공된 수치에 따르면 기준 가격은 주당 약 44달러입니다. 매도 예정인 주식은 회사의 총 발행 주식 4,462만 주 중 약 0.013%에 해당해, 비율상으로는 미미한 규모입니다.

해당 주식은 2021년 4월부터 2023년 4월 사이에 부여된 제한 주식 단위(RSU)와 성과 주식 단위(RPSU)의 여러 트랜치가 만기되면서 취득한 것입니다. 트랜치 크기는 191주에서 1,565주 사이로, 일반적인 주식 보상 관행을 반영합니다. 신고자는 지난 3개월 동안 판매가 없었다고 보고했으며, 공개되지 않은 중대한 부정적 정보가 없음을 인증했습니다.

Form 144는 제안된 판매에 대한 통지이며, 아직 완료된 것은 아닙니다. 제출서에는 판매자의 신원, Rule 10b5-1 거래 계획 존재 여부, 최종 실행 가격이 공개되어 있지 않습니다. 거래 규모가 작고 일상적인 인센티브 보상 만기에서 비롯된 점을 고려할 때, 이번 사건이 WLYB 주가에 중대한 영향을 미칠 가능성은 낮지만, 내부자 매도 패턴을 모니터링하는 투자자들에게는 참고 자료가 됩니다.

John Wiley & Sons, Inc. (WLYB) a déposé un formulaire 144 indiquant une intention de vente de 5 665 actions ordinaires via UBS Financial Services sur le NYSE, pour une valeur marchande totale de 250 053 $. Selon les chiffres fournis, le prix de référence est d'environ 44 $ par action. Les actions à vendre représentent environ 0,013 % des 44,62 millions d'actions en circulation, ce qui rend cette opération insignifiante en termes de pourcentage.

Les actions ont été acquises via la levée de plusieurs tranches d'unités d'actions restreintes (RSU) et d'unités d'actions de performance (RPSU) attribuées entre avril 2021 et avril 2023. La taille des tranches varie de 191 à 1 565 actions, reflétant les pratiques habituelles de rémunération en actions. Le déclarant a signalé aucune vente au cours des trois derniers mois et a certifié l'absence d'informations défavorables non divulguées.

Le formulaire 144 est un avis de ventes proposées, non encore réalisées. Le dépôt ne révèle pas l'identité du vendeur, l'existence éventuelle d'un plan de trading selon la règle 10b5-1, ni les prix finaux d'exécution. Étant donné la taille modeste de la transaction et son origine dans la levée habituelle de rémunérations incitatives, cet événement est peu susceptible d'influencer significativement le cours de l'action WLYB, mais reste une donnée à considérer pour les investisseurs surveillant les tendances de ventes internes.

John Wiley & Sons, Inc. (WLYB) hat ein Formular 144 eingereicht, das den beabsichtigten Verkauf von 5.665 Stammaktien über UBS Financial Services an der NYSE mit einem Gesamtmarktwert von 250.053 $ anzeigt. Basierend auf den angegebenen Zahlen liegt der Referenzpreis bei etwa 44 $ pro Aktie. Die zum Verkauf stehenden Aktien entsprechen ungefähr 0,013 % der 44,62 Millionen ausstehenden Aktien des Unternehmens, was die geplante Veräußerung in prozentualer Hinsicht unbedeutend macht.

Die Aktien wurden durch das Vesting mehrerer Tranchen von Restricted Stock Units (RSUs) und Performance Share Units (RPSUs) erworben, die zwischen April 2021 und April 2023 gewährt wurden. Die Tranchengrößen reichen von 191 bis 1.565 Aktien und spiegeln übliche Praktiken der Aktienvergütung wider. Der Meldende gab an, im vorangegangenen Dreimonatszeitraum keine Verkäufe getätigt zu haben, und bestätigte das Fehlen nicht offengelegter wesentlicher negativer Informationen.

Formular 144 ist eine Mitteilung über geplante, noch nicht abgeschlossene Verkäufe. Die Einreichung offenbart nicht die Identität des Verkäufers, ob ein Rule 10b5-1 Handelsplan besteht, oder die endgültigen Ausführungspreise. Angesichts der moderaten Größe der Transaktion und ihres Ursprungs aus routinemäßigem Anreiz-Vesting ist es unwahrscheinlich, dass das Ereignis den Aktienkurs von WLYB wesentlich beeinflusst, bleibt jedoch ein Datenpunkt für Investoren, die Insider-Verkaufsmuster beobachten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Puri Michal Nath

(Last) (First) (Middle)
C/O NOVOCURE INC.
1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)
WAYNE PA 19087

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Human Resources Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 06/30/2025 A V 833 A $15.13(2) 164,514 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c).
2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025.
Remarks:
Steven Robbins, as attorney in fact for Puri, Michal Nath 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is the size of the proposed insider sale for WLYB disclosed in Form 144?

The notice covers 5,665 shares with an estimated market value of $250,053.

What percentage of John Wiley & Sons’ outstanding shares does 5,665 shares represent?

The proposed sale equals roughly 0.013 % of the 44.62 million shares outstanding.

When is the earliest sale date mentioned in the Form 144 filing?

The filer lists an approximate sale date of July 1, 2025.

How were the shares to be sold originally acquired?

All shares originated from RSU and RPSU vesting events granted between April 2021 and April 2023.

Does the Form 144 confirm that the sale will occur?

No. Form 144 only provides notice of intent; actual sales will be confirmed, if completed, in subsequent Form 4 filings.
Novocure

NASDAQ:NVCR

NVCR Rankings

NVCR Latest News

NVCR Latest SEC Filings

NVCR Stock Data

1.91B
100.29M
9.78%
84.86%
4.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
Switzerland
ST. HELIER